Tangen Biosciences
Branford, US · Founded 2013 · Delaware corporation · 2 known investors
Founders & leadership
JR
John Richard NobileExecutive
JD
John DavidsonExecutive
Investors · 2
Reported raises · per SEC filings
Form D private placements$20.4M disclosed across 4 of 5 rounds · 2015–2023
▶$464.8KraisedJun 2023 · 9 investors · BiotechnologyRule 506(b)
▶$464.8KraisedJun 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan LevinDirector
- Richard C. Birkmeyer, PhDExecutive Officer, Director
- Vance V. KershnerDirector
- Daniel WagnerDirector
- Christopher McLeodDirector
- John DavidsonExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $464.8K
- Proceeds to insiders
- $75K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.2MraisedJul 2020 · 39 investors · BiotechnologyRule 506(b)
▶$11.2MraisedJul 2020 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher BenoitDirector
- Christopher McLeodDirector
- Brian ChiricoExecutive Officer
- Richard Birkmeyer, PhDExecutive Officer, Director
- John DavidsonExecutive Officer, Director
- Dan WagnerDirector
- Offering amount
- $20M
- Amount sold
- $11.2M
- Proceeds to insiders
- $375K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedMar 2019 · 29 investors · BiotechnologyRule 506(b)
▶$6.7MraisedMar 2019 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John DavidsonExecutive Officer, Director
- Dan WagnerDirector
- Christopher McLeodDirector
- Richard Birkmeyer, PhDExecutive Officer, Director
- Christopher BenoitDirector
- Offering amount
- $11.1M
- Amount sold
- $6.7M
- Proceeds to insiders
- $200K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MofferedNov 2016 · BiotechnologyRule 506(c)
▶$8MofferedNov 2016 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- John NobileDirector
- John DavidsonDirector
- Christopher BenoitDirector
- Christopher McLeodDirector
- Offering amount
- $8M
- Minimum investment
- $250K
- Proceeds to insiders
- $450K
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06c
▶$2MraisedDec 2015 · 8 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John Richard NobileExecutive Officer, Director, Promoter
- John DavidsonExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $2M
- Minimum investment
- $25K
- Proceeds to insiders
- $1
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $169K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $216K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who are Tangen Biosciences's investors?
- Tangen Biosciences's investors include Connecticut Innovations, Leading Edge Ventures.
- How much funding has Tangen Biosciences raised?
- Tangen Biosciences has disclosed $20.4M raised across 4 of its 5 known rounds.
- Where is Tangen Biosciences headquartered?
- Tangen Biosciences is headquartered in Branford, US.